Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hjorth-Hansen, Henrik, Stenke, Leif, Söderlund, Stina, Dreimane, Arta, Ehrencrona, Hans, Gedde-Dahl, Tobias, Gjertsen, Bjørn Tore, Höglund, Martin, Koskenvesa, Perttu, Lotfi, Kourosh, Majeed, Waleed, Markevärn, Berit, Ohm, Lotta, Olsson-Strömberg, Ulla, Remes, Kari, Suominen, Merja, Simonsson, Bengt, Porkka, Kimmo, Mustjoki, Satu, Richter, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365700/
https://www.ncbi.nlm.nih.gov/pubmed/25082346
http://dx.doi.org/10.1111/ejh.12423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365700/
https://www.ncbi.nlm.nih.gov/pubmed/25082346
http://dx.doi.org/10.1111/ejh.12423

Ejemplares similares